Patients, donors, and transplant characteristics
| . | PTCy-based GVHD prophylaxis, N = 313 . | ATG-based GVHD prophylaxis, N = 196 . | P . |
|---|---|---|---|
| Patient age, median (range), y | 46 (18-77) | 44 (18-76) | .52 |
| Patient sex, male (%) | 182 (58) | 110 (56) | .62 |
| Time from diagnosis to transplant, median (range), mo | 9 (2-121) | 9 (2-192) | .77 |
| AML/ALL, n (%) | 233 (74)/80 (26) | 140 (71)/56 (29) | .45 |
| Disease status at transplant, n (%) | |||
| CR1 | 117 (37) | 65 (33) | |
| CR ≥2 | 90 (29) | 47 (24) | .12 |
| Advanced (primary induction failure, relapse) | 106 (34) | 84 (43) | |
| Cytogenetic risk stratification, n (%)* | |||
| AML | |||
| Favorable | 22 (13) | 12 (10) | .78 |
| t(8;21)(q22;q22); RUNX1-RUNX1T1 | |||
| inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 | |||
| Mutated NPM1 without FLT3-ITD (normal karyotype) | |||
| Mutated CEBPA (normal karyotype) | |||
| Intermediate I | 82 (48) | 56 (46) | |
| Mutated NPM1 and FLT3-ITD (normal karyotype) | |||
| Wild-type NPM1 and FLT3-ITD (normal karyotype) | |||
| Wild-type NPM1 without FLT3-ITD (normal karyotype) | |||
| Intermediate II | 30 (18) | 22 (18) | |
| t(9;11)(p22;q23); MLLT3-MLL | |||
| Cytogenetic abnormalities not classified as favorable or adverse | |||
| Adverse | 37 (21) | 31 (26) | |
| inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 | |||
| t(6;9)(p23;q34); DEK-NUP214 | |||
| t(v;11)(v;q23); MLL rearranged | |||
| 5 or del(5q); −7; abnl(17p); complex karyotype | |||
| ALL | |||
| Standard | 18 (41) | 20 (43) | .80 |
| Poor | 26 (59) | 26 (57) | |
| Complex (>5 abn), t(9;22), t(4;11), t(8;14), hypodiploid | |||
| Donor age, median (range), y | 38 (13-70) | 39 (12-74) | .17 |
| Donor sex, male (%) | 170 (54) | 101 (52) | .54 |
| Female donor/male recipient, n (%) | 79 (25) | 55 (28) | .49 |
| CMV serostatus, donor/patient, n (%) | |||
| Negative/negative | 29 (9) | 28 (14) | .07 |
| Other combinations | 284 (91) | 168 (86) | |
| Intensity of conditioning regimen, n (%) | |||
| RIC | 140 (59) | 70 (36) | |
| MAC | 173 (41) | 126 (64) | <.01 |
| Donor stem cell source, n (%) | |||
| PB | 167 (53) | 142 (72) | |
| BM | 146 (47) | 54 (28) | <.01 |
| . | PTCy-based GVHD prophylaxis, N = 313 . | ATG-based GVHD prophylaxis, N = 196 . | P . |
|---|---|---|---|
| Patient age, median (range), y | 46 (18-77) | 44 (18-76) | .52 |
| Patient sex, male (%) | 182 (58) | 110 (56) | .62 |
| Time from diagnosis to transplant, median (range), mo | 9 (2-121) | 9 (2-192) | .77 |
| AML/ALL, n (%) | 233 (74)/80 (26) | 140 (71)/56 (29) | .45 |
| Disease status at transplant, n (%) | |||
| CR1 | 117 (37) | 65 (33) | |
| CR ≥2 | 90 (29) | 47 (24) | .12 |
| Advanced (primary induction failure, relapse) | 106 (34) | 84 (43) | |
| Cytogenetic risk stratification, n (%)* | |||
| AML | |||
| Favorable | 22 (13) | 12 (10) | .78 |
| t(8;21)(q22;q22); RUNX1-RUNX1T1 | |||
| inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 | |||
| Mutated NPM1 without FLT3-ITD (normal karyotype) | |||
| Mutated CEBPA (normal karyotype) | |||
| Intermediate I | 82 (48) | 56 (46) | |
| Mutated NPM1 and FLT3-ITD (normal karyotype) | |||
| Wild-type NPM1 and FLT3-ITD (normal karyotype) | |||
| Wild-type NPM1 without FLT3-ITD (normal karyotype) | |||
| Intermediate II | 30 (18) | 22 (18) | |
| t(9;11)(p22;q23); MLLT3-MLL | |||
| Cytogenetic abnormalities not classified as favorable or adverse | |||
| Adverse | 37 (21) | 31 (26) | |
| inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 | |||
| t(6;9)(p23;q34); DEK-NUP214 | |||
| t(v;11)(v;q23); MLL rearranged | |||
| 5 or del(5q); −7; abnl(17p); complex karyotype | |||
| ALL | |||
| Standard | 18 (41) | 20 (43) | .80 |
| Poor | 26 (59) | 26 (57) | |
| Complex (>5 abn), t(9;22), t(4;11), t(8;14), hypodiploid | |||
| Donor age, median (range), y | 38 (13-70) | 39 (12-74) | .17 |
| Donor sex, male (%) | 170 (54) | 101 (52) | .54 |
| Female donor/male recipient, n (%) | 79 (25) | 55 (28) | .49 |
| CMV serostatus, donor/patient, n (%) | |||
| Negative/negative | 29 (9) | 28 (14) | .07 |
| Other combinations | 284 (91) | 168 (86) | |
| Intensity of conditioning regimen, n (%) | |||
| RIC | 140 (59) | 70 (36) | |
| MAC | 173 (41) | 126 (64) | <.01 |
| Donor stem cell source, n (%) | |||
| PB | 167 (53) | 142 (72) | |
| BM | 146 (47) | 54 (28) | <.01 |
CR, complement receptor; MAC, membrane attack complex; MLL, mixed lineage leukemia.
Cytogenetic analysis was available for 75% of the total population; cytogenetic risk classification was assigned according to published criteria.47,48